Elsevier

Vaccine

Volume 25, Issue 41, 10 October 2007, Pages 7014-7016
Vaccine

Short communication
The feasibility of HIV vaccine efficacy trials among Russian injection drug users

https://doi.org/10.1016/j.vaccine.2007.07.028Get rights and content

Abstract

IDU exposure remains a primary driver of the Russian HIV epidemic, and recent incidence data provide little evidence that this epidemic is slowing. While there are multiple important challenges that need to be further explored before starting vaccine trials, most importantly access to evidence-based drug treatment services for trial participants, the current context of high HIV incidence and low genetic diversity of HIV strains, suggests the need for intensified prevention strategies and supports the feasibility of mounting efficacy trials of HIV vaccines among IDUs in the Russian Federation.

Introduction

There are estimated to be over 13 million injection drug users (IDUs) worldwide, and IDU in many settings are at high risk for HIV-1 acquisition [1]. IDU risks have been the predominant mode of HIV-1 spread in much of the Former Soviet Union and explosive spread of HIV among IDUs was documented through 1998–2001 in several Russian cities [2], [3]. Current estimates are that some 70–90% of HIV infections in the Russian Federation are attributable to injection drug use [4].

There is a growing consensus that a preventive HIV vaccine would be a key component in the global control of HIV spread [5]. Given the epidemiology of HIV in countries such as Russia, where parenteral exposure through IDU is the predominant mode of spread, it may be essential to investigate this route of transmission in HIV vaccine efficacy trials. If vaccine efficacy does differ by route of exposure, HIV vaccine candidates and strategies which have not been evaluated in the context of parenteral transmission could have limited utility in regions where this risk factor accounts for the majority of spread. One efficacy trial has been conducted in IDU, the Thai AIDSVAX trial among Bangkok IDU, but this remains an under-studied research domain. No efficacy trials with later-generation HIV vaccine candidates are currently underway among IDU.

Section snippets

The Russian context

The HIV Prevention Trial Network (HPTN) of the U.S. NIH conducted a multi-site cohort preparedness trial among IDUs in two Chinese cities and in St. Petersburg, Russia. This trial in Russia, which was funded by a grant to the University of North Carolina and the Biomedical Center (BC) in St. Petersburg, enrolled 520 IDUs between March and December of 2002 and followed them through to 2004. This study demonstrated a baseline HIV prevalence of 30% among IDUs and a measured HIV-1 incidence of

Site-specific challenges

There are many challenges in designing an effective HIV vaccine trial, particularly one implemented in a marginalized population such as IDUs. However, there are some challenges that are specific to the Russian context that need to be further explored and overcome before vaccine trials can proceed. UNAIDS has published a comprehensive guidance document outlining the specific ethical considerations when designing preventive HIV vaccine protocols [18]. One of the guidance points specifically

Conclusions

IDU exposure remains a primary driver of the Russian HIV epidemic, and recent incidence data provide little evidence that this epidemic is slowing. Studies of molecular epidemiology of the infecting strains have shown significant homogeneity of subtype A and relatively little increase in genetic diversity over the last 4 years. A preventive HIV vaccine would be an important addition to the arsenal used to prevent HIV transmission. And there are already vaccine candidates in the pipeline both in

Acknowledgements

The authors would like to acknowledge Charles Vitek, lead for the United States Centers for Disease Control activities in Russia for sharing his expertise of HIV vaccines and his insights into the dynamics of the Russian HIV epidemic.

Funding: The source of funding did not play a role in the interpretation of the data, or writing of the manuscript.

References (19)

  • E.M. Krupitsky et al.

    Naltrexone for heroin dependence treatment in St. Petersburg, Russia

    J Subst Abuse Treat

    (2004)
  • C. Aceijas et al.

    Global overview of injecting drug use and HIV infection among injecting drug users

    AIDS

    (2004)
  • M.G. Field

    HIV and AIDS in the Former Soviet Bloc

    N Engl J Med

    (2004)
  • K.L. Dehne et al.

    The HIV/AIDS epidemic in eastern Europe: recent patterns and trends and their implications for policy-making

    AIDS

    (May 7, 1999)
  • T. Rhodes et al.

    Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study

    Addiction

    (2006)
  • A.J. McMichael

    HIV vaccines

    Annu Rev Immunol

    (2006)
  • A.P. Kozlov et al.

    HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg, Russia

    AIDS

    (2006)
  • A.V. Shaboltas et al.

    HIV prevalence, sociodemographic, and behavioral correlates and recruitment methods among injection drug users in St. Petersburg, Russia

    J Acquir Immune Defic Syndr

    (2006)
  • T.V. Krasnoselskikh et al.

    Preliminary results of the laboratory follow-up on a group of injecting drug users within the framework of Randomized Controlled Trial of Russia IDU Peer Network HIV Prevention Intervention

    Russ J AIDS Cancer Public Health

    (2007)
There are more references available in the full text version of this article.

Cited by (9)

  • Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: Design and characterization of the enzymatic properties

    2014, Biochimie
    Citation Excerpt :

    Altogether, this motivates model studies of subtype B and non-subtype B HIV INs that would compare their susceptibility to antiretroviral drugs, evaluate the significance of early resistance mutations and identify the role of natural polymorphisms in the level of enzymatic activity. With this in mind, we have analyzed the naturally occurring variations in 34 full-length INs of HIV-1 subtype A strain predominant in the territory of the former Soviet Union (FSU-A) [35–40]. RAL-sensitive and resistant variants of the consensus FSU-A IN were created, and their enzymatic properties, including sensitivity to RAL and EVG, were examined in vitro.

  • Time to act: A call for comprehensive responses to HIV in people who use drugs

    2010, The Lancet
    Citation Excerpt :

    As data from the pre-exposure prophylactic trial become available,64 there might be a need to investigate pre-exposure prophylactic delivery for people who use drugs. Studies of new prevention technologies, including HIV vaccines, need to consistently include fully powered strata of people at risk via parenteral exposure; otherwise, the focus may fall on vaccines of uncertain effectiveness in the large populations where these risks predominate.65 People who use drugs are often the most knowledgable and skilled people in reaching their peers, including those outside treatment and care.66

View all citing articles on Scopus
View full text